FORGOTTEN HISTORY: Zepbound - The Untold Story

Dear Eli Lilly Stock Fans, Mark October 29 on Your Calendar

Eli Lilly’s weight-loss boom faces fierce competition, but its next earnings report could reveal why the best may still be ahead.

Barchart · Oct 26

LLY Stock Alert: What to Know as Eli Lilly Hits a New All-Time High

Eli Lilly stock printed a new all-time high yesterday. Here’s what has driven LLY shares higher and what comes next.

Barchart · Oct 21

GLP-1 Drugs Now Start as Low as $149 — But There’s a Catch

For Americans who have been priced out of popular weight-loss medications, a $149 monthly price tag sounds like welcome news. After years of seeing drugs...

Saving Advice · Oct 14

Medicare's New $50 GLP-1 Weight-Loss Program Just Launched: Find Out if You Qualify

Medicare's GLP-1 Bridge launched July 1, 2026. Up to 3.8M seniors may qualify for $50/month Wegovy, Zepbound, or Foundayo. Here's the eligibility breakdown.

Medical Daily · Jul 2

The $50 GLP-1 Bridge: How to Get Affordable Weight-Loss Meds Starting July 1

Beginning July 1, qualifying Medicare recipients will be able to take weight-loss drugs for $50 per month through the new Medicare GLP-1 Bridge program. However,...

Saving Advice · Jun 23

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand

Eli Lilly is launching Employer Connect to expand Zepbound access while its oral GLP-1 orforglipron just topped Novo Nordisk's Rybelsus in a head-to-head trial.

MarketBeat · Mar 15

Drugmaker Eli Lilly announces new plant in Pennsylvania as part of broader domestic expansion

Drugmaker Eli Lilly and Co. says it'll build a $3.5 billion manufacturing facility in Pennsylvania, as the company expands domestic production and capitalizes on surging sales of obesity and diabetes treatments

The Independent UK · Jan 30

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

MarketBeat · Jan 19

As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock?

Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

Barchart · Dec 3, 2025

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

Novo Nordisk’s (NYSE:NVO) nearly 11% pre-market drop on Monday and subsequent 9% dip at market open, in the aftermath of disappointing topline results from its evoke/evoke+ Alzheimer’s trials, is more than a pipeline setback.  It’s a stress test for healthcare ETFs that have quietly become GLP-1 momentum vehicles. With two…

Benzinga · Nov 24, 2025